Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.
Pharmacokinetic properties of many antineoplastic agents or their metabolites change with organ dysfunction. Unfortunately, chemotherapy doses determined in phase I and II studies in patients with normal hepatic and renal reserves are not usually applicable to those with hepatic and/or renal dysfunction. Considering the high incidence of colorectal adenocarcinoma, it is not unusual for a colorectal cancer patient to be on chronic hemodialysis. We report a patient with metastatic colorectal cancer on chronic hemodialysis who tolerated weekly irinotecan at 50 mg/m2 well without significant toxicity. We briefly discuss therapeutic dose modification in such patients.
Budakoglu
B
B
Ankara Numune Egitim ve Aractirma Hastanesi, Tlbbi Onkoloji Klinigi, Ankara, Turkey. burbudak@hotmail.com
Abali
H
H
Uncu
D
D
Yildirim
N
N
Oksüzoglu
B
B
Zengin
N
N
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000628:therapy; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D018570:Risk Assessment; D016896:Treatment Outcome
D000077146:Irinotecan; D002166:Camptothecin